Heipos received 50 million financing domestic gene sequencing brewing outbreak

In addition to the 10 million financing provided by Hypros, the “leading” Huada Gene of the gene sequencing industry will also actively plan to go public. Under the influence of favorable policies, China's genetic sequencing is brewing out, and the prospects are promising.

Haipulos recently announced that the company has completed a 50-yuan A round of financing, including top VC lead investment, and three other companies participated in the investment. Hypros is mainly engaged in the genetic testing business, using advanced foreign genetic testing and analysis technology to carry out cancer personalized drug prevention and early cancer screening.

In the forthcoming “13th Five-Year Plan” for the pharmaceutical industry, precision medicine will benefit from good harvesting policies. As the core technology of precision medicine , gene sequencing has been so busy in the capital world. In addition to the 10 million financing provided by Hypros, the “leading” Huada Gene of the gene sequencing industry will also actively plan to go public. Under the influence of the above factors, China's genetic sequencing is brewing out, and the prospects are promising.

Numerous disease and gene-related gene sequencing is of great value

Gene sequencing is a technique for detecting DNA, which is a technique for detecting DNA by blood, other liquids or cells. At present, gene sequencing has undergone four generations of innovative development, and has reached the level of clinical popularization and application in terms of cost, flux level and accuracy.

Modern medicine has proven that except for injuries, almost all human diseases are genetically related. The development of gene sequencing technology can predict the risk of illness in advance and treat it in time.

For example, in cancer, there are 3.1 million new cases of cancer and 2.2 million deaths every year in China. Gene sequencing technology can achieve early cancer screening, which can remind patients to pay attention and timely treatment, and reduce the incidence of disease and mortality. As the disease spectrum continues to change, the country vigorously improves the medical level, and the national health awareness increases, the value of future gene sequencing will become increasingly prominent.

Therefore, our policy has begun to tilt towards the field of gene sequencing. During the “two sessions” in 2016, precision medicine encountered multiple policy catalysis: on March 5th, precision medicine (genomics) was selected into 13 major projects of 13 and 5; on March 8, the Ministry of Science and Technology announced the release of national key research and development. Plan for the 2016 Special Project Reporting Guidelines for Accurate Medical Research (referred to as the “National Guide”); on March 9th, Precision Medicine first entered the CPPCC proposal, and CPPCC members proposed to establish a database of Chinese genetic resources for various diseases. Develop an accurate medical plan...

Interpretation of the gene sequencing industry chain to improve the upstream and downstream links in China

The gene sequencing industry chain can be divided into upstream equipment and consumable supplies, midstream gene sequencing services and downstream bioinformatics data analysis. More specific division methods are: upstream sequencing instruments, middle and upstream capture and sequencing consumables (including sequencing consumables and sequencing instruments), midstream sequencing services, mid-stream and downstream sequencing data analysis and cloud platform, downstream is medical testing center, including sequencing data The interpretation and the issuance of medical diagnostic reports.

Gene sequencing industry chain

In the upstream sector, foreign companies such as Illumina, Roche, Pacific, and Lifetech occupy major markets, among which US companies are at the forefront of the world, especially in the field of genetic sequencers;

The mid-stream gene sequencing service technology has a low threshold, and only needs to purchase sequencing instruments and reagents to provide sequencing services. At present, the market for gene sequencing services such as hospitals, research institutions, and pharmaceutical companies in China is basically occupied by Huada Gene, Berry, and Kanghe Annoyouda, which have the advantages of technology and cost;

The downstream is the biological information data link, which is currently starting late and has a small base, which is not enough attention. With the support of the policy, China's gene sequencing industry has gradually developed, but it is mainly concentrated in the lower middle reaches of the threshold, and the upstream and downstream links have yet to be strengthened.

3 billion yuan market liquid biopsy technology is a bright spot

In 2013, the global market for sequencing products and services was about US$5 billion. If the market size of downstream applications for gene sequencing is added, this figure will reach more than US$20 billion. After the estimate, the annual average growth rate (CAGR) will increase by 22%. The global market for sequencing products and services will reach 20 billion US dollars, and the downstream application space will be more than 100 billion US dollars.

2015-2020 global gene sequencing market size forecast (unit: billion US dollars)

Source: Prospective Industry Research Institute

According to the "2016-2021 China Gene Sequencing Industry Market Prospect and Investment Strategic Planning Report" provided by Forward Industry Research Institute, in recent years, sequencing companies with Huada Gene as the leading company have achieved more than 100% compound growth, 2007-2010 4 During the year, the income of DNA sequencing in China increased by 200% every year. It is expected that the scale of the gene sequencing market in 2015 will exceed 3 billion yuan.

Driven by both policy and market, the investment in genetic sequencing has opened. Forward-looking Industry Research Institute believes that the largest area of ​​gene sequencing applications is cancer prediction. The liquid biopsy technology for early detection of cancer will be the largest application market in the gene sequencing industry through a small number of body fluid companies that can quickly detect tumor mutations.

Compared with the traditional tumor detection method, it shortens the detection time, reduces the detection cost, and avoids the process of surgery and puncture sampling in the traditional detection process, and thus has an excellent development prospect in the medical field.

At present, China's liquid biopsy market is quietly forming. According to incomplete statistics, there are currently 47 companies engaged in tumor liquid biopsy. Among them, 26 companies choose ctDNA (circulating tumor DNA) route, and 9 companies choose CTC (circulating tumor cell) business. . Representative enterprises include Huada Gene, WuXi PharmaTech, Burning Stone, and Universal Huakang.

Laser Distance Sensor

Leading Laser Measure Module Factory in China
The World's First single transmitting single receiving design laser module, which has a big help to reduce producing cost and power consumption of the laser distance sensor.
This Laser distance sensor has high Accuracy up to ±1 mm, working as phase measure, which support RS232/RS422/RS485/Arduino to TTL communication.
This laser distance module is widely used in the Laser Distance Meter industry, also a very good choice for the Industrial applications. Most of measuring tools manufactures is purchasing from us in China.

Product Specifications:

Range Sensor,Laser Distance Module,Distance Sensor,Laser Measure Sensor

Chengdu JRT Meter Technology Co., Ltd , https://www.accuracysensor.com